Lab breakthrough: new method supercharges immune cells against Kids' cancers
NCT ID NCT07240207
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to improve how immune cells (called CTLs) are grown in the lab so they can better recognize and kill pediatric solid tumors like neuroblastoma and osteosarcoma. Researchers are using a special device called a G-Rex bioreactor to produce larger numbers of these cells while keeping them young and active. The work is still in the lab phase, using tumor samples from 44 children, and has not yet been tested in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cytotoxic T lymphocytes (CTLs) grown in a special bioreactor
- What this could lead to
- If successful, this research could lead to better ways to produce immune cells that attack pediatric solid tumors, potentially improving future cell therapies for children.
- What could go wrong
- This is a very early laboratory study, not yet tested in patients. The cells may not work as well in real children, and many steps are needed before any treatment becomes available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo, SC Chirurgia Pediatrica
RECRUITINGPavia, Pavia, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.